GlassScriptPhysician profile
Vijay Maurya
NPI 1538251830
$3,170.81
in general payments reported to CMS, 2019-2025
15 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $149 · 2021: $407 · 2022: $437 · 2023: $591 · 2024: $717 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,077.54 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $515.91 | 2019-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $412.01 | 2019-2023 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $358.51 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $188.73 | 2023-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $168.13 | 2023-2024 | Auvelity |
| Neurocrine Biosciences, INC. | $98.05 | 2019 | |
| Lundbeck LLC | $97.13 | 2019-2021 | |
| Corium, LLC | $89.65 | 2023 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $50.06 | 2020 | |
| Indivior INC. | $31.62 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $28.91 | 2019 | |
| Edwards Lifesciences Corporation | $23.17 | 2021 | |
| Greenwich Biosciences, INC. | $17.17 | 2021 | |
| Janssen Scientific Affairs, LLC | $14.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Maurya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.